Skip to content
OpenCapital
Get started

Crinetics Pharmaceuticals CRNX Business Segments — Research And Development Stock Based Compensation

Similar metrics at other companies

Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Research and development expenses (excluding stock-based compensation)
$73.72M+106%
Apogee Therapeutics, Inc. logo
APGEReportable Segment Aggregation Before Other Operating — Research And Development Personnel Related Excluding Equity Based Compensation
$18.54M+21.2%
Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%
Dolby Laboratories, Inc. logo
DLBReportable Segment — R&D
$53.84M+2.2%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Research and development compensation and personnel-related expenses
$11.05M+14.6%
Pegasystems logo
PEGAReportable Segment — R&D
$82.05M+10.4%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0×0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept crnx:ResearchAndDevelopmentStockBasedCompensation.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's business segments — research and development stock based compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's business segments — research and development stock based compensation?
Crinetics Pharmaceuticals (CRNX) reported business segments — research and development stock based compensation of $19.33M in Q1 2026.
How has Crinetics Pharmaceuticals's business segments — research and development stock based compensation changed year-over-year?
Crinetics Pharmaceuticals's business segments — research and development stock based compensation increased by 63.5% year-over-year, from $11.82M to $19.33M.
What does business segments — research and development stock based compensation mean?
This metric quantifies the non-cash expense related to stock-based awards granted to research and development personnel. It reflects the company's strategy for incentivizing and retaining scientific talent through equity participation. This is a key component of total R&D investment and impacts the company's overall operating expenses.